211 related articles for article (PubMed ID: 38589664)
1. Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.
Prosz A; Sahgal P; Huffman BM; Sztupinszki Z; Morris CX; Chen D; Börcsök J; Diossy M; Tisza V; Spisak S; Likasitwatanakul P; Rusz O; Csabai I; Cecchini M; Baca Y; Elliott A; Enzinger P; Singh H; Ubellaker J; Lazaro JB; Cleary JM; Szallasi Z; Sethi NS
NPJ Precis Oncol; 2024 Apr; 8(1):87. PubMed ID: 38589664
[TBL] [Abstract][Full Text] [Related]
2. RAD51-Mediated DNA Homologous Recombination Is Independent of
Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
[TBL] [Abstract][Full Text] [Related]
3. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
Petrelli A; Rizzolio S; Pietrantonio F; Bellomo SE; Benelli M; De Cecco L; Romagnoli D; Berrino E; Orrù C; Ribisi S; Moya-Rull D; Migliore C; Conticelli D; Maina IM; Puliga E; Serra V; Pellegrino B; Llop-Guevara A; Musolino A; Siena S; Sartore-Bianchi A; Prisciandaro M; Morano F; Antista M; Fumagalli U; De Manzoni G; Degiuli M; Baiocchi GL; Amisano MF; Ferrero A; Marchiò C; Corso S; Giordano S
Cancer Res; 2023 May; 83(10):1699-1710. PubMed ID: 37129948
[TBL] [Abstract][Full Text] [Related]
4. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
Diossy M; Sztupinszki Z; Borcsok J; Krzystanek M; Tisza V; Spisak S; Rusz O; Timar J; Csabai I; Fillinger J; Moldvay J; Pedersen AG; Szuts D; Szallasi Z
NPJ Precis Oncol; 2021 Jun; 5(1):55. PubMed ID: 34145376
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
6. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
7. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
Börcsök J; Sztupinszki Z; Bekele R; Gao SP; Diossy M; Samant AS; Dillon KM; Tisza V; Spisák S; Rusz O; Csabai I; Pappot H; Frazier ZJ; Konieczkowski DJ; Liu D; Vasani N; Rodrigues JA; Solit DB; Hoffman-Censits JH; Plimack ER; Rosenberg JE; Lazaro JB; Taplin ME; Iyer G; Brunak S; Lozsa R; Van Allen EM; Szüts D; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Apr; 27(7):2011-2022. PubMed ID: 33208343
[TBL] [Abstract][Full Text] [Related]
8. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
[TBL] [Abstract][Full Text] [Related]
9. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
11. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract][Full Text] [Related]
12. Functional profiling of nucleotide Excision repair in breast cancer.
Rajkumar-Calkins AS; Szalat R; Dreze M; Khan I; Frazier Z; Reznichenkov E; Schnorenberg MR; Tsai YF; Nguyen H; Kochupurakkal B; D'Andrea AD; Shapiro GI; Lazaro JB; Mouw KW
DNA Repair (Amst); 2019 Oct; 82():102697. PubMed ID: 31499327
[TBL] [Abstract][Full Text] [Related]
13. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z
Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115
[TBL] [Abstract][Full Text] [Related]
14. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
van Wijk LM; Nilas AB; Vrieling H; Vreeswijk MPG
Expert Rev Mol Diagn; 2022 Feb; 22(2):185-199. PubMed ID: 34913794
[TBL] [Abstract][Full Text] [Related]
15. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
Mekonnen N; Yang H; Shin YK
Front Oncol; 2022; 12():880643. PubMed ID: 35785170
[TBL] [Abstract][Full Text] [Related]
16. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
[TBL] [Abstract][Full Text] [Related]
17. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Börcsök J; Diossy M; Sztupinszki Z; Prosz A; Tisza V; Spisak S; Rusz O; Stormoen DR; Pappot H; Csabai I; Brunak S; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Jul; 27(13):3734-3743. PubMed ID: 33947694
[TBL] [Abstract][Full Text] [Related]
18. Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue.
van Wijk LM; Vermeulen S; Ter Haar NT; Kramer CJH; Terlouw D; Vrieling H; Cohen D; Vreeswijk MPG
Breast Cancer Res Treat; 2023 Dec; 202(3):607-616. PubMed ID: 37725154
[TBL] [Abstract][Full Text] [Related]
19. Functional Homologous Recombination (HR) Screening Shows the Majority of
Meijer TG; Martens JWM; Prager-van der Smissen WJC; Verkaik NS; Beaufort CM; van Herk S; Robert-Finestra T; Hoogenboezem RM; Ruigrok-Ritstier K; Paul MW; Gribnau J; Bindels EMJ; Kanaar R; Jager A; van Gent DC; Hollestelle A
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398132
[TBL] [Abstract][Full Text] [Related]
20. Development of Homologous Recombination Functional Assays for Targeting the DDR.
Oswald AJ; Gourley C
Cancer Treat Res; 2023; 186():43-70. PubMed ID: 37978130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
